[March 15, 2017] |
|
Seven Bridges Announces Scientific Advisory Board
Seven
Bridges, the biomedical data analysis company, today announced its
Scientific Advisory Board, which formalizes relationships with leading
global experts in genomic medicine, bioinformatics and cancer research.
Members of the Seven Bridges Scientific Advisory Board will advise on
the company's product designs and strategies for cloud-based biomedical
data analysis, as well as share their knowledge about key challenges and
opportunities in the field of genomic research.
The inaugural members of the Seven Bridges Scientific Advisory Board
include:
-
Dr. James Knight, Director of Bioinformatics and Research
Scientist at The
Knight Lab at Yale University. Established in the summer of 2014,
the Knight Lab holds a joint appointment with Yale's Department
of Genetics and the Yale
Center for Genome Analysis. Dr. Knight's focus in the Genetics
department is the alignment, variant calling and annotation of exome
sequencing and whole genome sequencing datasets, both for cohorts of
research samples and for individual clinical samples. His focus for
the YCGA is providing bioinformatics support to Yale (and non-Yale)
investigators who utilize YCGA's next-generation sequencing facility.
Prior to his role at Yale, Dr. Knight was an R&D Fellow and
Bioinformatics Director at 454 Life Sciences and CuraGen Corporation,
and has been active in the bioinformatics field for the last 25 years.
-
Dr. Jan Korbel, Principal Investigator and Senior Scientist at
the European
Molecular Biology Laboratory (EMBL) in Heidelberg, Germany.
Holding a Ph.D. in Molecular Biology, he performed his Postdoc at Yale
University where he co-developed the paired-end mapping methodology
for characterizing genomic structural variation by next-generation
sequencing. With expertise in Human Genetics and Computational
Biology, Dr. Korbel is particularly interested in understanding
determinants of genomic DNA rearrangement formation and selection, for
example in the context of enhancer hijacking or catastrophic DNA
alterations (chromothripsis). He has a leading role in the Pan-Cancer
Analysis of Whole Genomes Initiative, and was elected into the German
National Academy of Sciences Leopoldina in 2015, and into the European
Molecular Biology Organisation (EMBO) in 2016.
-
Dr. Charles Lee, Scientific Director and Professor, The
Jackson Laboratory (JAX) for Genomic Medicine. Dr. Lee is a
distinguished biomedical scientist who first discovered widespread
structural variation in the human genome in 2004, in the form of copy
number variation (CNV). Prior to joining JAX, he was on the faculty at
Harvard Medical School and a clinical laboratory geneticist at Brigham
and Women's Hospital in Boston. He is also a Fellow of the American
College of Mdical Genetics (FAMG) and the president of the Human
Genome Organisation (HUGO International). Dr. Lee's honors include
a Scientific Award from the American Association for Cancer Research,
the 2008 Ho-Am Prize in Medicine, and the George Brumley Jr. Memorial
Award from Duke University. He is also an elected fellow of the
American Association for the Advancement of Science and a Thompson
Reuters (News - Alert) Citation Laureate. In 2012, he received the Chen Global
Investigator Award from HUGO.
-
Dr. Heng Li, a research scientist at the Broad
Institute, working with David Reich and David Altshuler to
understand the genetic causes of disease. He is currently focusing on
the analysis of new sequencing data, population genetics and
phylogenetics and is the principal developer of several bioinformatics
projects, including SAMtools, BWA, MAQ, TreeSoft and TreeFam. Prior to
joining the Broad Institute, Dr. Li was a postdoctoral fellow
of Richard Durbin at the Wellcome
Trust Sanger Institute, and was also previously involved as a
Group Leader in several projects at Beijing Genomics Institute (BGI),
Chinese Academy of Science.
-
Dr. Gholson Lyon, head of Cold
Spring Harbor Laboratory's Lyon Lab and research scientist at the Utah
Foundation for Biomedical Research. His group focuses on human
genetics and genomic medicine, with an emphasis on diseases with
severe neuropsychiatric manifestations, including Tourette syndrome,
attention-deficit hyperactivity disorder (ADHD), obsessive compulsive
disorder (OCD), autism and schizophrenia. Dr. Lyon studied
biochemistry and molecular biology as an undergraduate at Dartmouth
College, received an M.Phil. in genetics from the University of
Cambridge, England and a Ph.D. in pharmacology and peptide chemistry
at Rockefeller University. He received his M.D. from Weill Cornell
Medical College. He started his independent research career in 2009,
after finishing clinical residencies in child, adolescent and adult
psychiatry. In addition to his research on the genetics of
neuropsychiatric illnesses, Dr. Lyon is focusing on the genetic basis
of rare Mendelian diseases and the development of clinical-grade exome
and whole genome sequencing.
-
Dr. Gokhan Hotamisligil, James S. Simmons Professor of Genetics
& Metabolism, Chair, Department of Genetics & Complex Diseases,
Director, Sabri
Ülker Center for Metabolic Research; Assoc. Member, Harvard-MIT (News - Alert)
Broad Institute, Harvard
Stem Cell Institute, Joslin
Diabetes Center. Dr. Hotamisligil's research efforts focus on the
molecular and genetic basis of common and complex diseases,
particularly obesity, diabetes, and heart disease. His research
examines the mechanisms of nutrient sensing and response pathways as
they relate to immune and metabolic homeostasis. He is an
internationally recognized leader with seminal contributions including
the discoveries that defined immunological components of obesity and
diabetes, discovery of novel hormones regulating lipid and glucose
metabolism, and endoplasmic reticulum as a key organelle regulating
cellular and organismic metabolism, and its role in obesity, insulin
resistance, and diabetes. Dr. Hotamisligil pursues interdisciplinary
paths, collaborations, and industry alliances towards development of
novel preventive and therapeutic strategies against chronic metabolic
diseases. His work has resulted in >180 highly cited papers and
resulted in multiple patents. Dr. Hotamisligil has been recognized
with fellowships and awards including Markey, Pew (News - Alert), and AAAS
Fellowships, the Outstanding Scientific Accomplishment Award of ADA,
Wertheimer Award from IASO, Koç Science Award, TUBITAK Science Award,
Roy Greep Award of the Endocrine Society, and the International Danone
Prize. He earned his M.D. at Ankara University and Ph.D. at Harvard
University.
"As we continue to build on Seven Bridges' vision to connect the world's
biomedical data for better research and health, input from leaders in
the fields of genetics, bioinformatics and cancer research will prove
invaluable to our efforts," said Brandi Davis-Dusenbery, CEO of Seven
Bridges. "We are honored that these respected experts have agreed to
participate in our SAB and look forward to working with them to
constantly advance the state of the art in data analysis for our
large-scale pharmaceutical and government clients."
About Seven Bridges
Seven Bridges is the biomedical data analysis company accelerating
breakthroughs in genomics research for cancer, drug development and
precision medicine. The scalable, cloud-based Seven Bridges Platform
empowers rapid, collaborative analysis of millions of genomes in concert
with other forms of biomedical data. Thousands of researchers in
government, biotech, pharmaceutical and academic labs use Seven Bridges,
including three of the largest genomics projects in the world: U.S.
National Cancer Institute's Cancer
Genomics Cloud pilot, the Million
Veteran Program, and Genomics England's 100,000
Genomes Project. As the NIH's only commercial Trusted Partner, Seven
Bridges authenticates and authorizes access to one of the world's
largest cancer genomics dataset. Named one of the world's smartest
companies by MIT Technology Review, Seven Bridges has offices in
Cambridge, Mass.; Belgrade; London; Istanbul; and San Francisco.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170315005606/en/
[ Back To TMCnet.com's Homepage ]
|